All In Biotech

Drug Trial Radar · NCT03249207

SC IL-1Ra in SAH - Phase III Trial (SCIL)

Does Interleukin-1 Receptor Antagonist Improve Outcome Following Aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III Trial

Last checked: Nov 20, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 612 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

612

Actual

Start

Oct 11, 2018

Primary completion

Apr 2024

Study completion Sep 2024

Sponsor

Lead sponsor
University of ManchesterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute for Health Research, United Kingdom; Clinical Trials Unit, Manchester; Northern Care Alliance NHS Foundation Trust
First posted
Aug 15, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial will establish whether IL-1Ra, with sub-cutaneous (SC) administration twice daily for up to 21 days post aneurysmal subarachnoid haemorrhage (aSAH), improves clinical outcome as measured by ordinal shift in mRS at 6 months. Patients with SAH transferred to a neurosurgical centre will be identified and approached for study participation. Following consent, patients will be randomised to receive either IL-1Ra or placebo for a maximum of 21 days from onset of symptoms. Patients who are found to be non-aneurysmal following randomisation will be withdrawn from the study treatment. Blood samples for plasma IL-6 will be obtained prior to randomisation and at day 3-5 post randomisation for IL-6 \& IL-1 measurement. Safety will be measured at 30 days post randomisation and outcome assessed at 6 months post randomisation.

Conditions

  • Subarachnoid Hemorrhage

Interventions

  • IL-1RaDrug

    Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).

  • IL-1Ra PlaceboDrug

    Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ordinal shift in modified Rankin Score (mRS)Time frame: 6 months post randomisation

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Sussex County Hospital

    Brighton, United Kingdom

  • Southmead Hospital

    Bristol, United Kingdom

  • Addenbrookes Hospital

    Cambridge, United Kingdom

  • The Walton Centre

    Liverpool, United Kingdom

  • Royal London Hospital

    London, United Kingdom

  • St George's Hospital

    London, United Kingdom

  • Charing Cross Hospital

    London, United Kingdom

  • National Hospital for Neurology and Neurosurgery, Queen Square

    London, United Kingdom

  • Northern Care Alliance NHS Foundation Trust

    Manchester, United Kingdom

  • Queens Medical Centre

    Nottingham, United Kingdom

  • Royal Preston Hospital

    Preston, United Kingdom

  • Southampton General Hospital

    Southampton, United Kingdom

  • Royal Stoke University Hospital

    Stoke-on-Trent, United Kingdom

  • Derriford Hospital

    Plymouth, Devon, United Kingdom

  • Royal Hallamshire Hospital

    Sheffield, South Yorkshire, United Kingdom

  • University Hospital of Wales

    Cardiff, Wales, United Kingdom

  • Leeds General Infirmary

    Leeds, Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.